Approval of inhaled nitric oxide by the US Food and Drug Administration for
hypoxic respiratory failure of the term and near-term newborn provides an
important new therapy for this serious condition. This statement addresses
the conditions under which inhaled nitric oxide should be administered to t
he neonate with hypoxic respiratory failure.